Local Regulatory Experts
Connect with regulatory affairs consultancies specializing in this region.
Qualtech Consulting Corporation
Taiwan, China, Japan, Singapore, Hong Kong, Malaysia, Philippines, Vietnam, Australia, Germany, Korea, Thailand, USA
A specialized medical device consulting firm offering a one-stop solution for complex global regulatory challenges. We offer real-time regulatory and clinical support, local representation, and QMS services across 13 markets, ensuring efficient market entry and compliance.
Cobridge Co., Ltd.
Tokyo, Japan
We assist medical device companies with the medical device registration and approval in Japan. Regulatory consulting services and DMAH services for foreign manufacturers to enter Japanese market.
MDREX, Medical Device, Digital Health Consulting Group
Seoul, Republic of Korea (HQ), Japan Office
We offer total solutions for market entry in South Korea and global expansion (e.g., Japan, USA, Europe). Key areas include product approval, reimbursement listings (HIRA), and Quality System certification (KGMP). They are particularly strong in innovative products like SaMD, medical wearables, and 3D printing for medical use, and provide in-depth expertise in cybersecurity and clinical trial planning.
CMIC Holdings Co., Ltd.
Tokyo, Japan (HQ), Osaka, Japan, Beijing, China, Seoul, South Korea, Taipei, Taiwan, Singapore, New York, USA, London, UK, Frankfurt, Germany, Sydney, Australia
We operate globally, specializing in accelerating the development, manufacturing, and commercialization of drugs and medical devices. Their expertise spans Phase I to IV clinical trials, regulatory affairs, quality assurance, and manufacturing, with a strong focus on the Japanese and Asian markets. Key services include clinical operations (CRO), manufacturing (CDMO/CMO), site management (SMO), and comprehensive health analysis and solutions.
November 1, 2025
Approximately 5 minutes
Standards for Marketing Approval of Antipruritic and Anti-inflammatory Drugs in Japan
Standards for Marketing Approval of Antipruritic and Anti-inflammatory Drugs (Japan)
The Standards for Marketing Approval of Antipruritic and Anti-inflammatory Drugs were issued as Notification PFSB No.1101-1 on November 1, 2011. These standards specify regulatory criteria for external dermal medicines primarily containing adrenocortical hormones or antihistamines intended to relieve itching and inflammation of the skin. Preparations not conforming to these standards require submission of supporting efficacy and safety data and justification for combinations. (PMDA, 000272502.pdf).
Scope
The standards apply to medicines mainly containing adrenocortical hormones or antihistamines for dermal application formulated as antipruritic and anti-inflammatory drugs. (PMDA, 000272502.pdf).
Types of Active Ingredients
- Permissible active ingredients and grouping rules are defined in the table within the standards.
- At least one active ingredient from Column I or Column II must be present.
- Preparations mainly containing Column I ingredients may include ingredients from Columns II, III, IV, V, VI, VII, VIII, IX, X or XII.
- Preparations mainly containing Column II ingredients may include those from Columns III, IV, V, VI, VII, VIII, IX, X, XI or XII.
- Only one active ingredient per column I, II, IV, V, VII, VIII or IX is permitted; some groups in Columns X and XII also limit the number of ingredients. (PMDA, 000272502.pdf).
Quantities of Active Ingredients
- Maximum concentration for each active ingredient is specified in the table.
- The minimum concentration for many ingredients (Columns II, III, V, VI, VIII, certain groups in X and XII, Column XI) is 1/5 of the maximum; for ingredients mainly in Group 1 of Column I or Group 2 of Column II the minimum must be at least half the maximum.
- For ingredients listed in Columns IV, VII, IX and certain groups in Columns X and XII, the minimum concentration is 1/10 of the maximum. (PMDA, 000272502.pdf).
Dosage Forms
Approved forms include liquids for external use, sprays, ointments, creams and gels. Preparations with Column I active ingredients are excluded from the spray category. (PMDA, 000272502.pdf).
Dosage and Administration
The preparation should be applied to the skin surface several times a day, and the method of application must be clearly indicated on labeling and instructions. (PMDA, 000272502.pdf).
Indications
Indications depend on the main active ingredient groups:
- Group 1 of Column I: eczema, dermatitis, miliaria, irritated skin, itching, chilblains, insect bites, urticaria.
- Group 2 of Column I: eczema, dermatitis, miliaria, irritated skin, itching, insect bites, urticaria.
- Column II: eczema, dermatitis, skin sore, miliaria, irritated skin, itching, chilblains, insect bites, urticaria. (PMDA, 000272502.pdf).
Summary
These standards establish the regulatory framework for marketing approval of antipruritic and anti-inflammatory dermal medicines in Japan, including permitted active ingredients, concentration limits, dosage forms, application methods, and indications to ensure safety and efficacy. (PMDA, 000272502.pdf).
Have a Question?
Ask our experts about this topic. We'll do our best to respond to your question.
Related Articles
Approximately 5 minutes
Standards for Marketing Approval of Ophthalmic Medicines in Japan
Regulatory criteria for ophthalmic medicines in Japan
Approximately 5 minutes
Standards for Marketing Approval of Vitamin Preparations in Japan
Regulatory criteria for oral vitamin preparations in Japan
Approximately 5 minutes
Standards for Marketing Approval of Enemas in Japan
Regulatory criteria for enemas in Japan
Approximately 5 minutes
Standards for Marketing Approval of Anthelmintics in Japan
Regulatory criteria for anthelmintics in Japan
Approximately 5 minutes
Standards for Marketing Approval of Nasal Drops for Rhinitis in Japan
Regulatory criteria for nasal drops for rhinitis in Japan
Approximately 5 minutes
Standards for Marketing Approval of Antihemorrhoids (External Preparations) in Japan
Regulatory criteria for external antihemorrhoid medicines in Japan